Harvard Apparatus Regenerative Technology, Inc. 8-K

What Happened
Harvard Apparatus Regenerative Technology, Inc. filed an 8-K (Item 5.07) reporting the results of its Annual Meeting of Stockholders held on June 18, 2026. The company announced the election of three Class I directors — Junli (Jerry) He, James Shmerling, and Mao Zhang — each for a one-year term ending at the 2027 annual meeting. Stockholders also ratified the appointment of CBIZ CPAs P.C. as the company’s independent registered public accounting firm for fiscal 2026 and approved, in a non-binding advisory vote, the compensation of the company’s named executive officers.

Key Details

• Director elections (plurality vote; options were "For" or "Withheld"):
  • Junli (Jerry) He: 12,802,162 For; 859,270 Withheld; 1,274,478 Broker non-votes.
  • James Shmerling: 10,725,274 For; 2,936,158 Withheld; 1,274,478 Broker non-votes.
  • Mao Zhang: 12,804,230 For; 857,202 Withheld; 1,274,478 Broker non-votes.
• Auditor ratification (Proposal 2): CBIZ CPAs P.C. approved — 14,077,329 For; 5,417 Against; 853,164 Abstained; 0 Broker non-votes.
• Executive compensation (Proposal 3, non-binding): Approved — 12,467,264 For; 39,284 Against; 1,154,884 Abstained; 1,274,478 Broker non-votes.
• Filing date of the 8-K: June 24, 2026.

Why It Matters
These votes finalize the company’s short-term board composition and confirm its auditor for fiscal 2026, both of which affect governance and financial reporting oversight. The director tallies show strong support for He and Zhang and higher withholding for Shmerling, but all three were elected under plurality rules. The executive pay vote passed as a non-binding advisory matter—useful as a gauge of shareholder sentiment but not legally binding. Broker non-votes and abstentions impacted vote totals and should be noted when assessing shareholder consensus.